Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old at the start of Screening Visit~* A documented diagnosis of adult-onset axial SpondyloArthritis (axSpA) and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria for axSpA~* Subjects must have had back pain for at least 12 months before Screening~* No sacroiliitis defined by Modified New York (mNY) criteria on sacroiliac (SI) x-rays~* Active disease at Screening as defined by~  * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4~ * Spinal pain \>= 4 on a 0 to 10 Numerical Rating Scale (NRS)~* Inadequate response to, have a contraindication to, or have been intolerant to at least 2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)~Exclusion Criteria:~* Diagnosis of AS or any other Inflammatory Arthritis~* Prior treatment with any experimental biological agents for treatment of Axial SpondyloArthritis (SpA)~* Exposure to more than 1 tumor necrosis factor (TNF)-antagonist or primary failure to TNF antagonist therapy~* History of or current chronic or recurrent infections~* Subjects with known Tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent Tuberculosis (LTB)~* Recent live vaccination~* Concurrent malignancy or a history of malignancy~* Class III or IV congestive heart failure - New York Heart Association (NYHA)~* Demyelinating disease of the central nervous system~* Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product~* Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol 200 mg Q2W (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.

Based on this trial design, predict the completion outcome and termination type (if applicable).